Tokio Marine Asset Management Co. Ltd. Trims Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Tokio Marine Asset Management Co. Ltd. lowered its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 5.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 44,965 shares of the biopharmaceutical company’s stock after selling 2,836 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Bristol-Myers Squibb were worth $2,307,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in BMY. GHP Investment Advisors Inc. grew its position in shares of Bristol-Myers Squibb by 6.8% during the third quarter. GHP Investment Advisors Inc. now owns 6,076 shares of the biopharmaceutical company’s stock worth $343,000 after purchasing an additional 386 shares in the last quarter. B.O.S.S. Retirement Advisors LLC grew its holdings in Bristol-Myers Squibb by 15.6% during the 3rd quarter. B.O.S.S. Retirement Advisors LLC now owns 4,365 shares of the biopharmaceutical company’s stock valued at $253,000 after buying an additional 589 shares in the last quarter. Boston Trust Walden Corp grew its holdings in Bristol-Myers Squibb by 5.3% during the 3rd quarter. Boston Trust Walden Corp now owns 15,258 shares of the biopharmaceutical company’s stock valued at $886,000 after buying an additional 771 shares in the last quarter. Riverwater Partners LLC grew its holdings in Bristol-Myers Squibb by 17.7% during the 3rd quarter. Riverwater Partners LLC now owns 4,583 shares of the biopharmaceutical company’s stock valued at $266,000 after buying an additional 689 shares in the last quarter. Finally, Strategic Blueprint LLC grew its holdings in Bristol-Myers Squibb by 8.6% during the 3rd quarter. Strategic Blueprint LLC now owns 5,440 shares of the biopharmaceutical company’s stock valued at $316,000 after buying an additional 431 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

BMY has been the subject of several research analyst reports. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Wells Fargo & Company raised their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th. Bank of America lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $68.00 to $60.00 in a research note on Wednesday, January 3rd. Finally, StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 15th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $61.18.

Bristol-Myers Squibb Stock Down 8.6 %

BMY stock traded down $4.20 on Thursday, hitting $44.66. 28,510,607 shares of the company’s stock were exchanged, compared to its average volume of 15,669,466. Bristol-Myers Squibb has a 12-month low of $44.37 and a 12-month high of $69.74. The firm has a 50 day moving average price of $51.22 and a two-hundred day moving average price of $51.31. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43. The stock has a market cap of $90.52 billion, a P/E ratio of 11.70, a price-to-earnings-growth ratio of 1.48 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The company had revenue of $11.87 billion during the quarter, compared to analysts’ expectations of $11.45 billion. During the same quarter in the previous year, the firm posted $2.05 EPS. The firm’s revenue was up 4.7% compared to the same quarter last year. As a group, equities research analysts expect that Bristol-Myers Squibb will post 6.63 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 annualized dividend and a dividend yield of 5.37%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 62.18%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.